Clinical trial · Observational
Methylated DNA Detect in Paraneoplastic Syndrome of Nervous System
A Research of Value of Free Methylated DNA Detect in Lung Cancer on the Diagnosis and Treatment of Paraneoplastic Syndrome of Nervous System
NCT04454853CI-TRIAL-00045836completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to verify whether the cell-free DNA of lung cancer in the blood can be used as a biomarker for early diagnosis and prognosis evaluation of patient with paraneoplastic syndrome of the nervous system.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Paraneoplastic Neurological Syndrome | — | UNRESOLVED | — |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Lung cancer | Other | — | UNRESOLVED |
| Positive methylated DNA | Other | — | UNRESOLVED |
| Suspected lung cancer | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- label
- Lung cancer with positive methylated DNA
- description
- Blood DNA methylation abnormalities are found in lung cancer.
- interventionNames
- Other: Lung cancer
- Other: Positive methylated DNA
- label
- Lung cancer with negative methylated DNA
- description
- Blood DNA methylation abnormalities are not found in lung cancer.
- interventionNames
- Other: Lung cancer
- label
- Suspected lung cancer with positive methylated DNA
- description
- Blood DNA methylation abnormalities are found in suspected lung cancer.
- interventionNames
- Other: Suspected lung cancer
- Other: Positive methylated DNA
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * The agnogenic typical neurological syndromes (including encephalomyelitis, marginal encephalitis, subacute cerebellar degeneration, strabismus ocular clonic-myoclonus, subacute sensory neuron disease, Lambert-Eaton myasthenic syndrome, skin Myositis, etc.) patient who predisposed to a tumor. * Pathologically confirmed as lung cancer or suggested as lung cancer patient by imaging (pulmonary CT/Positron Emission Tomography-CT), tumor biomarkers, anti-brain tissue antibodies, etc. Exclusion Criteria: * Lacunar infarction * Aortic atherosclerotic cerebral infarction * Clear cardiogenic cerebral infarction * Other related system diseases (arteritis, vascular dissection, migraine and vasospasm, etc.)
References
Publications (0)
Data not yet available
No reference posted for this study.